Valuation: Semler Scientific, Inc.

Market Cap 232M 203M 192M 175M 328M 22.22B 330M 2.3B 890M 11.35B 870M 851M 36.48B P/E 2023
16.8x
P/E 2024 10.5x
Enterprise Value 217M 190M 180M 164M 307M 20.79B 309M 2.15B 833M 10.62B 815M 797M 34.14B EV / Sales 2023
3.53x
EV / Sales 2024 8.63x
Free-Float
97.04%
Yield 2023 *
-
Yield 2024 -
1 day-1.11%
Current year+36.92%
Current year 13.7
Extreme 13.7
20.2
1 year 13
Extreme 13
28
3 years 13
Extreme 13
74
5 years 13
Extreme 13
128.66
10 years 13
Extreme 13
128.66
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 2022-11-30
Corporate Secretary 45 2026-01-15
Director TitleAgeSince
Director/Board Member 41 2026-01-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%-.--% - - 311M
-0.26%+0.41%+27.97%+29.02% 12.59B
-0.04%+1.76%+15.83%+21.21% 6.65B
-2.25%-8.31% - - 5.75B
+0.87%+2.59%+33.69%+25.63% 5.57B
-3.88%-3.16%-26.62%+34.04% 4.89B
-1.49%+1.03%-30.58%-22.64% 3.91B
-2.22%-5.09%+23.94%-8.65% 1.89B
+1.37%-2.64%-14.49%+189.22% 1.66B
-0.33%-0.81%+48.78%-13.48% 1.57B
Average -0.90%-1.33%+9.82%+31.79% 4.94B
Weighted average by Cap. -0.82%-0.79%+12.73%+25.90%

Financials

2023 2024
Net sales 68.18M 59.83M 56.51M 51.5M 96.4M 6.54B 97.09M 676M 262M 3.34B 256M 250M 10.73B 56.29M 49.4M 46.65M 42.52M 79.59M 5.4B 80.16M 558M 216M 2.76B 211M 207M 8.86B
Net income 20.58M 18.06M 17.06M 15.55M 29.1M 1.97B 29.31M 204M 79.06M 1.01B 77.28M 75.61M 3.24B 40.9M 35.89M 33.9M 30.89M 57.82M 3.92B 58.24M 406M 157M 2B 154M 150M 6.44B
Net Debt -57.04M -50.05M -47.27M -43.08M -80.64M -5.47B -81.21M -566M -219M -2.79B -214M -210M -8.98B -14.85M -13.03M -12.31M -11.21M -20.99M -1.42B -21.14M -147M -57.04M -727M -55.75M -54.55M -2.34B
Logo Semler Scientific, Inc.
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Employees
79